Matthew Kapusta

Pharma

UniQure gives up on $1M+ gene therapy Glybera

UniQure's trailblazing gene therapy has met its end. After struggling for years with the ultraexpensive Glybera, the company is calling it quits on the drug.

Eric Sagonowsky Apr 20, 2017 10:21am